First human safety and pharmacokinetic study of a plasmalogen augmentation therapy published by MLD

MLD is thrilled to announce that it has published the results of its successful first-in-human Phase I study of its synthetic plasmalogen precursor drug PPI-1011. The Phase I study was completed in Canada and evaluated the safety, tolerability, and pharmacokinetic properties of PPI-1011 in healthy adults. PPI-1011 is a synthetic plasmalogen precursor being developed as a treatment for diseases of plasmalogen deficiency.

For more information about the publication and its importance to the PPi-1011 drug program see the formal news release at MLD announces positive first-in-human Phase I results of its synthetic plasmalogen precursor drug PPI-1011. - BioSpace

A copy of the manuscript is available at First‐In‐Human Safety, Tolerability, and Pharmacokinetics of PPI‐1011, a Synthetic Plasmalogen Precursor